Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
UBS
Cipla
Covington
Medtronic
Dow
Mallinckrodt
Harvard Business School
Federal Trade Commission

Generated: May 27, 2018

DrugPatentWatch Database Preview

Flutemetamol f-18 - Generic Drug Details

or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for flutemetamol f-18 and what is the scope of flutemetamol f-18 patent protection?

Flutemetamol f-18
is the generic ingredient in one branded drug marketed by Ge Healthcare and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Flutemetamol f-18 has seventy-six patent family members in twenty-three countries.

One supplier is listed for this compound.
Summary for flutemetamol f-18
International Patents:76
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 1
Clinical Trials: 18
Patent Applications: 14
DailyMed Link:flutemetamol f-18 at DailyMed
Pharmacology for flutemetamol f-18
Synonyms for flutemetamol f-18
((18 sup)F)AH110690
[18F]-Flutemetamol
[18F]-Flutemetamol F18
[18F]AH110690
[18F]flutemetamol
18F-Flutemetamol
2-(3-((18 sup)F)Fluoro-4-(methylamino)phenyl)-1,3-benzothiazol-6-ol
2-(3-(sup 18)f)Fluoro-4-(methylamino)phenyl)-1,3-benzothiazol-6-ol
2-[3-((18)F)fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol
2-[3-(18F)fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol
6-Benzothiazolol, 2-(3-(fluoro-(sup 18)F)-4-(methylamino)phenyl)-
765922-62-1
CHEBI:76611
CHEMBL2042122
D10231
DB09151
DTXSID80227394
Flutemetamol
flutemetamol ((18)F)
Flutemetamol ((sup 18)F)
Flutemetamol ((sup18)F)
flutemetamol (18F)
Flutemetamol (18F) [INN]
Flutemetamol F 18
Flutemetamol F 18 (USAN)
Flutemetamol F 18 [USAN]
flutemetamol F 18 injection
Flutemetamol F18
GTPL7342
L49M066S0O
SCHEMBL10032147
UNII-L49M066S0O
Vizamyl
Vizamyl (TN)

US Patents and Regulatory Information for flutemetamol f-18

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Non-Orange Book US Patents for flutemetamol f-18

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,911,707 Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition ➤ Try a Free Trial
7,854,920 Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition ➤ Try a Free Trial
9,833,458 Thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition ➤ Try a Free Trial
9,808,541 Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Supplementary Protection Certificates for flutemetamol f-18

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
15/005 Ireland ➤ Try a Free Trial PRODUCT NAME: VIZAMYL-FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822
C0005 France ➤ Try a Free Trial PRODUCT NAME: FLUTEMETAMOL (18 F); REGISTRATION NO/DATE: EU/1/14/941 20140822
634 Luxembourg ➤ Try a Free Trial PRODUCT NAME: FLUTEMETAMOL (18F) ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (VIZAMYL). FIRST REGISTRATION: 20140826
C0006 France ➤ Try a Free Trial PRODUCT NAME: FLUTEMETAMOL (18 F); REGISTRATION NO/DATE: EU/1/14/941 20140822
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Healthtrust
Daiichi Sankyo
US Army
Covington
Cantor Fitzgerald
McKinsey
Queensland Health
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.